 Connection
Tejas Patil to Biomarkers, Tumor
This is a "connection" page, showing publications Tejas Patil has written about Biomarkers, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.432 |
|
|
|
-
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T. High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. Clin Lung Cancer. 2026 Jun; 27(5):96-105.
Score: 0.143
-
Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 11; 21(6):545-552.e1.
Score: 0.095
-
Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):e191-e204.
Score: 0.092
-
Riely GJ, Wood DE, Aisner DL, Axtell AL, Bauman JR, Bharat A, Chang JY, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Levy B, Lin J, Loo BW, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patil T, Polanco PM, Riess J, Mendez ALR, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yau E, Yun K, Gregory K, Hang L. Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Apr; 24(4).
Score: 0.036
-
Klein M, Watson D, Castro M, Kapoor S, Nair PR, Rajagopalan S, Qin H, Glaser M, Westanmo A, Lala DA, Kumar A, Chauhan J, G P, Ullal YS, Kulkarni S, Narvekar Y, Ghosh A, Tyagi A, Patil M, Macpherson MD, Wingrove JA, Patil T, Aggarwal C, Ganti AK. Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors. Clin Lung Cancer. 2026 May; 27(4):5-13.
Score: 0.035
-
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2024 05; 22(4):249-274.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|